News Column

Vernalis Initiates Phase Ib/II POC Study of V81444

Jul 12 2013 12:00AM



WINNERSH, UK -- (Marketwired) -- 07/12/13 --

12 July 2013LSE: VER Vernalis Initiates Phase Ib/II Proof-of-Concept Study with V81444Vernalis plc today announces that it has dosed the first subjects in aPhase Ib/II proof-of-concept (PoC) study of V81444, anA2Aantagonistwhich has potential applications for the treatment of Parkinson'sdisease and other disorders of the central nervous system (CNS).The randomised, double-blind, placebo controlled study will evaluatethe safety, tolerability and pharmacokinetics of V81444 after twicedaily administration for 14 days in 24 subjects. As the study is beingconducted in subjects with a confirmed diagnosis of one of thepotential indications, the aim is also to provide initial proof ofconcept for use of V81444 as a potential treatment for this CNSindication. The trial is being conducted at a single US site under anapproved Investigational New Drug (IND) application. -- ends --Enquiries:Vernalis Contacts:Ian Garland, Chief Executive Officer +44 (0) 118 938 0015David Mackney, Chief Financial OfficerNomura Code Securities Limited: +44 (0) 20 7776 1200Juliet ThompsonJonathan SeniorBrunswick Group: +44 (0) 20 7404 5959Jon ColesNotes to EditorsAbout VernalisVernalis is a revenue generating development stage pharmaceuticalcompany with significant expertise in drug development. The Group hasone marketed product, frovatriptan for the acute treatment of migraine,an exclusive licensing agreement to develop and commercialise multiplenovel products focussed on the US prescription cough/cold market aswell as seven programmes in its NCE development pipeline. Vernalis hassignificant expertise in fragment and structure based drugdiscoverywhich it leverages to enter into collaborations with largerpharmaceutical companies. The Company's technologies, capabilities andproducts are endorsed by collaborations with Endo, Genentech, Lundbeck,Menarini, Novartis, Servier and Tris.For further information about Vernalis, please visit www.vernalis.comVernalis Forward-Looking StatementThis news release may contain forward-looking statements that reflectthe Company's current expectations regarding future events includingthe clinical development and regulatory clearance of the Company'sproducts, the Company's ability to find partners for the developmentand commercialisation of its products, as well as the Company's futurecapital raising activities. Forward-looking statements involve risksand uncertainties. Actual events could differ materially from thoseprojected herein and depend on a number of factors including thesuccess of the Company's research strategies, the applicability of thediscoveries made therein, the successful and timely completion ofclinical studies, the uncertainties related to the regulatory process,the ability of the Company to identify and agree beneficial terms withsuitable partners for the commercialisation and/or development of itsproducts, as well as the achievement of expected synergies from suchtransactions, the acceptance of frovatriptan and other products byconsumers and medical professionals, the successful integration ofcompleted mergers and acquisitions and achievement of expectedsynergies from such transactions, and the ability of the Company toidentify and consummate suitable strategic and business combinationtransactions. This information is provided by RNS The company news service from the London Stock ExchangeEND

Email Contact

Source: Marketwire

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters